Allegra Patent Rulings
This article was originally published in The Pink Sheet Daily
Executive Summary
Five generic companies do not infringe two composition patents for Aventis' Allegra (fexofenadine), a Newark, N.J. federal judge ruled June 29
You may also be interested in...
Teva Launches Generic Allegra Tablets Despite Patent Litigation
Marketing agreement between Barr, which is waiving its exclusivity, and Teva would allow the companies to share the litigation hazard of the "at risk" launch.
Teva Launches Generic Allegra Tablets Despite Patent Litigation
Marketing agreement between Barr, which is waiving its exclusivity, and Teva would allow the companies to share the litigation hazard of the "at risk" launch.
Express Scripts Anticipates Growth In 2005 From Zithromax, Zofran Generics
PBM cites anticipated contribution to growth from several first-time generics that could enter the market in 2005. Nevertheless, Express Scripts concedes that generic utilization growth will be weaker in 2005 than in other years. Subsidiary CuraScript will aid PBM's growth by converting clients that use an outside specialty pharmacy provider.